The pharma major fell more than 5 per cent in a week which triggered the breakdown from a 50-point range where Rs 700 acted as a stiff resistance while levels of Rs 658-660 and above acted as strong support. The stock closed at Rs 652 on 26 August 2022.
Midcap, smallcap valuations still overpriced despite recent correction: Shibani Sircar Kurian
The private sector banks, particularly large-cap ones, appear to have valuations that accommodate current headwinds. Large-caps offer attractive investment opportunities compared to mid-caps and small-caps,
January 15, 2025